Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.

ABSTRACT:

Purpose of review

Therapies that target the immune system are increasingly used across oncology, including in hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While allogeneic transplant has been a key therapy in these cancers, new approaches that target the immune system are being explored including immune checkpoint therapies, antibody-drug conjugates, and cellular therapies.

Recent findings

This review outlines updates in the preclinical rationale for immune directed therapies in MDS and AML, as well as recent clinical trials exploring these therapies. This manuscript summarizes the development of therapies targeting T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and CD47, which are being evaluated in

SUBMITTER: Brunner AM 

PROVIDER: S-EPMC10017015 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature